Compile Data Set for Download or QSAR
Report error Found 139 of affinity data for UniProtKB/TrEMBL: P03420
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50516304(CHEMBL4468815)
Affinity DataEC50:  2.10E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D489A mutant expressed in Hep2 cells as reduction in virus induced cytopathic effect b...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50516304(CHEMBL4468815)
Affinity DataEC50: >1.00E+4nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells as reduction in virus induced cytopathic effect b...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541840(CHEMBL4639630)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541841(CHEMBL4646240)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541842(CHEMBL4647328)
Affinity DataEC50:  440nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541843(CHEMBL4641371)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541844(CHEMBL4648059)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541845(CHEMBL4638156)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541846(CHEMBL4632659)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541847(CHEMBL4646870)
Affinity DataEC50: >1.00E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541848(CHEMBL4640616)
Affinity DataEC50:  8.10nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541849(Presatovir | GS-5806)
Affinity DataEC50:  1.19E+3nMAssay Description:Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554856(CHEMBL4740044)
Affinity DataEC50:  0.270nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554857(CHEMBL4752948)
Affinity DataEC50:  17nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554858(CHEMBL4750881)
Affinity DataEC50:  0.330nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554859(CHEMBL4747256)
Affinity DataEC50:  0.870nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554860(CHEMBL4757367)
Affinity DataEC50:  1.70nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554861(CHEMBL4779491)
Affinity DataEC50:  2.10nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554862(CHEMBL4758615)
Affinity DataEC50:  7nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554863(CHEMBL4741045)
Affinity DataEC50:  2.70nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554864(CHEMBL4747375)
Affinity DataEC50:  0.810nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554865(CHEMBL4761881)
Affinity DataEC50:  4.60nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554866(CHEMBL4753413)
Affinity DataEC50:  1.40nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554867(CHEMBL4752460)
Affinity DataEC50:  1.40nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554868(CHEMBL4746117)
Affinity DataEC50:  54nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554869(CHEMBL4782630)
Affinity DataEC50:  21nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554870(CHEMBL4742185)
Affinity DataEC50:  2.5nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554871(CHEMBL4756466)
Affinity DataEC50:  17nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50541848(CHEMBL4640616)
Affinity DataEC50:  2nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554872(CHEMBL4751254)
Affinity DataEC50:  1.10nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554873(CHEMBL4752524)
Affinity DataEC50:  1.10nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554874(CHEMBL4746199)
Affinity DataEC50:  0.740nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554875(CHEMBL4765002)
Affinity DataEC50:  0.770nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554876(CHEMBL4747540)
Affinity DataEC50:  0.470nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554877(CHEMBL4755451)
Affinity DataEC50:  0.640nMAssay Description:Inhibition of F protein in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effect incubated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554858(CHEMBL4750881)
Affinity DataEC50:  3.10nMAssay Description:Inhibition of F protein D486N mutant in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effe...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM50554856(CHEMBL4740044)
Affinity DataEC50:  0.700nMAssay Description:Inhibition of F protein D486N mutant in Respiratory syncytial virus A2 infected in HepG2 cells assessed as reduction in virus-induced cytopathic effe...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534197(WO2022081973, Example 1 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  570nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534198(WO2022081973, Example 2 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  5.00E+3nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534199(WO2022081973, Example 3 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  350nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534200(WO2022081973, Example 4 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  540nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534201(WO2022081973, Example 67 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  50nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534202(WO2022081973, Example 6 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  570nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534203(WO2022081973, Example 7 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  360nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534204(WO2022081973, Example 8 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  160nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534205(WO2022081973, Example 9 | ((2R,3S,4R,5R)-5-(4-amin...)
Affinity DataEC50:  490nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534206(WO2022081973, Example 10 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  55nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534207(WO2022081973, Example 11 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  47nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534208(WO2022081973, Example 12 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  240nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

TargetFusion glycoprotein F0(Human respiratory syncytial virus A (strain A2))
Roche Pharma Research and Early Development

Curated by ChEMBL
LigandPNGBDBM534209(WO2022081973, Example 13 | ((2R,3S,4R,5R)-5-(4-ami...)
Affinity DataEC50:  240nMAssay Description:Antiviral activity of compounds against SARS-CoV-2 is evaluated as described in Xue, Xi et al.2020. Briefly, the human alveolar epithelial cell line ...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022081973

Displayed 1 to 50 (of 139 total ) | Next | Last >>
Jump to: